文献速递重症综合管理与镇静镇痛

褪黑素与重症监护病房谵妄:随机对照试验的系统评价与Meta分析

Melatonin and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Intensive Care Med · 2025-10-06
一句话结论与安慰剂相比,褪黑素未降低重症患者谵妄发生率(RR 0.89,95%CI 0.73-1.09),对病死率亦无影响。

该系统评价与Meta分析检索MEDLINE、Embase和Web of Science至2025年7月5日,纳入评估褪黑素用于重症患者的随机对照试验。主要分析仅纳入各结局偏倚风险低至中度的6项RCT共2209例患者,褪黑素组谵妄发生率与对照组无差异(RR 0.89,95%CI 0.73-1.09);纳入13项RCT共2830例的次要分析结果一致(RR 0.86,95%CI 0.70-1.04)。主要分析(7项RCT,2165例)与次要分析(8项RCT,2396例)均未发现褪黑素与病死率相关。结果提示与安慰剂相比,褪黑素不减少重症患者谵妄发生率,对病死率亦无影响。

要点

  • 主要分析(6项低至中度偏倚风险RCT,2209例):褪黑素组谵妄发生率与对照组无差异,RR 0.89(95%CI 0.73-1.09)。
  • 次要分析(13项RCT,2830例):褪黑素对谵妄发生率的结果与主要分析一致,RR 0.86(95%CI 0.70-1.04)。
  • 主要分析(7项RCT,2165例):褪黑素与病死率无关联,RR 0.87(95%CI 0.73-1.02)。
  • 次要分析(8项RCT,2396例):褪黑素与病死率无关联,RR 0.92(95%CI 0.79-1.06)。
  • 作者结论:与安慰剂相比,褪黑素不降低重症患者谵妄发生率,对病死率亦未观察到效果。

适用人群与场景

  • 重症患者(纳入评估褪黑素用于重症患者的随机对照试验人群)

研究设计与关键结果

  • 研究类型:随机对照试验的系统评价与Meta分析,检索MEDLINE、Embase和Web of Science自建库至2025年7月5日,注册号PROSPERO CRD420251041661。
  • 主要分析基于6项低至中度偏倚风险RCT共2209例患者,褪黑素组谵妄发生率与对照组无差异(RR 0.89,95%CI 0.73-1.09)。
  • 次要分析纳入13项RCT共2830例患者,谵妄发生率结果与主要分析一致(RR 0.86,95%CI 0.70-1.04)。
  • 主要分析(7项RCT,2165例)未发现褪黑素与病死率相关(RR 0.87,95%CI 0.73-1.02)。
  • 次要分析(8项RCT,2396例)未发现褪黑素与病死率相关(RR 0.92,95%CI 0.79-1.06)。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析。
  • 主要分析仅纳入各结局偏倚风险低至中度的试验,次要分析纳入全部试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论提示:与安慰剂相比,褪黑素不降低重症患者谵妄发生率,对病死率亦未观察到效果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delirium is frequent in critically ill patients and is associated with increased mortality. Discrepancies were found in the results of recent randomized controlled trials (RCTs) regarding the effect of melatonin to prevent delirium onset in critically ill patients.

METHODS: We searched MEDLINE, Embase, and Web of Science from inception to 5 July 2025 for RCTs evaluating melatonin in critically ill patients. The primary outcome was the incidence of delirium. The main secondary outcome was mortality. We generated pooled risk ratios (RR). To base our conclusions on the highest quality of evidence, our primary analysis was based only on the trials with low to moderate risk of bias for each outcome. A secondary analysis was conducted, including all the trials. The study was registered with PROSPERO (CRD420251041661).

FINDINGS: Our primary analysis was based on six RCTs with 2209 patients and did not show any difference in the incidence of delirium attributable to the treatment with melatonin (RR 0.89, [95% confidence interval (CI) 0.73-1.09]). This result was consistent with the secondary analysis including thirteen RCTs with 2830 patients (RR 0.86, [95% CI 0.70-1.04]). No association was found between mortality and melatonin in the primary (seven RCTs, 2165 patients, RR 0.87, [95% CI 0.73-1.02]) and secondary (8 RCTs, 2396 patients, RR 0.92, [95% CI 0.79-1.06]) analyses.

INTERPRETATION: The results suggest that compared to placebo, melatonin does not reduce delirium incidence in critically ill patients. Similarly, no effect was observed on mortality.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lakbar I, Poole D, Delamarre L, et al. Melatonin and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Intensive Care Med. 2025. PMID: 41051561. doi:10.1007/s00134-025-08143-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。